AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 3, 2026, 4:11 PM ET Stoke Therapeutics reports third-quarter 2026 revenue of $11.3M and net loss of $73.6M AI-generated summary · Source: press report
BiotechGenetic medicinesDevelopment risk

STOK Stock Hub: Stoke Therapeutics News, Zorevunersen and RNA Medicines

RNA medicines for genetic disease : zorevunersen in Dravet syndrome, the EMPEROR pivotal study and an earlier optic-atrophy program. The clinical value depends on controlled benefit, durable safety and practical adoption.

Last updated: November 3, 2026Market reference: November 2, 2026 regular-session closeFinancial period: Quarter and nine months ended September 30, 2026Currency: U.S. dollars unless stated
Full research report · PDF
Stoke Therapeutics ($STOK), research as of October 29, 2026
15 pages covering Archived research examines zorevunersen’s RNA mechanism, early Dravet observations and the controlled EMPEROR study. It separates cognitive and seizure endpoints, Biogen rights, OSPREY optic-atrophy development, September financial updates, equity funding and the sequence from clinical results to a possible regulatory submission. This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Get the report (PDF)
Next company-guided operating milestone
By year-end 2026

Completion of dosing in the third OSPREY cohort.

Initial STK-002 data are expected in H1 2027; EMPEROR topline is guided to Q3 2027, followed by the planned U.S. NDA in H2 2027. The next dated company events are investor-conference presentations by CEO Ian F. Smith and Chief Patient Officer Jason Hoitt on November 10 (Guggenheim, 1:00 p.m. ET) and November 17 (Jefferies London, 11:00 a.m. ET). Conference announcement
Stoke Therapeutics STOK daily stock chart
Daily chart $STOK. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

STOK stock at a glance

Close · November 2, 2026
$26.48
Regular-session close; +0.72% versus $26.29 on October 30, 2026.
Lead medicine
Zorevunersen
Investigational ASO for Dravet syndrome Source
Pivotal study
EMPEROR phase 3
162-patient primary-analysis cohort enrolled June 2026; about 110 patients through Week 28 and no discontinuations as of October 29, 2026 Source
Pivotal readout
Q3 2027
Company forecast dated October 5, 2026 Source
September liquidity
$358.8M
Cash, equivalents and marketable securities at September 30, 2026 (June 30: $354.3M; about $420M pro forma after the August ATM) Source
Q3 net loss
$73.6M
$1.08 per share, quarter ended September 30, 2026; R&D $59.8M, SG&A $28.7M, revenue $11.3M Source
H1 operating cash use
$117.2M
Six months ended June 30, 2026, the latest filed cash-flow statement Source
Funding horizon
Early 2028
Company forecast of October 29, 2026: cash expected to fund operations into early 2028 Source

Where Stoke Therapeutics stands now

Stoke Therapeutics is developing zorevunersen for Dravet syndrome by increasing functional NaV1.1 protein from the unaffected SCN1A copy. EMPEROR is testing whether the early signals translate into a controlled benefit on seizures and adaptive function. The October 5 FDA update clarified a planned Vineland-3 analysis and the path to an H2 2027 NDA, with phase 3 data expected in Q3 2027; on October 29 the company reported that about 110 of 162 primary-analysis patients had passed Week 28, the primary-endpoint time point, with no discontinuations. Biogen holds rights outside the United States, Canada and Mexico. The central questions are clinical magnitude, durability, safety, financing and practical adoption, while STK-002 adds an earlier ophthalmology opportunity.

Enrollment and treatment retention are not randomized efficacy. EMPEROR remains the controlled pivotal test. Early clinical observations and prespecified secondary-endpoint plans say nothing about the future result; partner rights, development costs and capital needs remain material.

The constructive case

Zorevunersen targets an underlying protein deficiency in a severe disease, with encouraging early seizure and adaptive-function observations, a fully enrolled U.S. primary-analysis cohort and Biogen’s support outside retained North American markets. A persuasive controlled result could establish differentiated clinical value.

The cautious case

The pivotal controlled result remains ahead. Early studies were open-label; invasive repeat administration, long-term safety, endpoint interpretation, competition, regulatory execution and further share dilution can all limit the outcome. A positive seizure result may still leave the broader disease-modification thesis unproven.

Read also: Praxis $PRAX $RAPP $STOK $XENE: Beyond Seizure Counts →

Latest Stoke Therapeutics news

Nov 3, 2026

Stoke Therapeutics reports third-quarter 2026 revenue of $11.3M and net loss of $73.6M

Stoke Therapeutics reported third-quarter 2026 revenue of $11.3M. Net loss was $73.6M, or $(1.08) per share, according to the 10-Q summary. Reported by the press from an official company announcement; the primary document was not yet available in our sources at the time of writing.

Nov 3, 2026

Stoke Therapeutics to present at upcoming investor conferences in November

Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA, on Tuesday, November 10, 2026. They will also present at the 2026 Jefferies London Global Healthcare Conference in London, UK, on Tuesday, November 17, 2026. Live webcasts and archived replays will be available in the Investors & News section of Stoke's website.

Oct 29, 2026

Third-quarter results: EMPEROR progress, FDA alignment and $358.8 million of cash

Stoke reported third-quarter 2026 results and a business update on October 29, 2026. In the phase 3 EMPEROR study of zorevunersen, global enrollment is complete. As of October 29, all 162 patients in the primary-analysis population (U.S., U.K. and Japan) are through Week 8, about 130 are through Week 24, about 110 are through Week 28 (the time point of the primary endpoint, change in major motor seizure frequency), about 65 are through Week 40 and about 20 are through Week 52; all of these 20 continue into the open-label period and no patient has discontinued treatment. Enrollment of 34 patients in Europe was completed in August and of 5 patients in China in October. The data readout remains guided to the third quarter of 2027, followed by the planned U.S. NDA in the second half of 2027. After a meeting with the FDA, the company plans to analyze cognition and behavior, a key secondary endpoint, with a multicomponent assessment of four prespecified Vineland-3 subdomains, and to submit data to the FDA throughout the first half of 2027. For STK-002 in autosomal dominant optic atrophy, dosing is complete in the first two OSPREY cohorts and under way in the third (expected to complete by the end of 2026), with the fourth cohort expected in early 2027 and initial safety and efficacy data in the first half of 2027. Cash, cash equivalents and marketable securities were $358.8 million at September 30, 2026, which the company expects to fund operations into early 2028. Revenue was $11.3 million (from $10.6 million); net loss was $73.6 million, or $1.08 per share, against $38.3 million, or $0.65 per share, a year earlier; R&D expenses were $59.8 million and SG&A expenses $28.7 million. For the nine months, net loss was $185.3 million, or $2.81 per share. Source (Exhibit 99.1)

Oct 22, 2026

Third-quarter business and financial update scheduled for October 29

Stoke scheduled its next business and financial update for October 29. The announcement sets the calendar for the next results and program discussion; it contains no new pivotal efficacy results. Source

Oct 16, 2026

Employee option grants accompany organizational expansion

Stoke announced options covering 245,920 shares for 18 new employees, effective October 15 and subject to vesting. The grants create potential future dilution rather than an immediate issuance of the same number of common shares. Source

Oct 12, 2026

STK-002 advances through OSPREY dose cohorts

At AAO, Stoke presented ADOA natural-history and preclinical evidence and reported completion of dosing in OSPREY's first two cohorts. Third-cohort dosing is expected to finish by year-end, with initial safety and efficacy data in H1 2027. Source

STOK stock catalysts: development and reporting dates

  • November 10, 2026 · 1:00 p.m. ET — Presentation, Guggenheim 3rd Annual Healthcare Innovation Conference (Boston). Scheduled company event
  • November 17, 2026 · 4:00 p.m. GMT / 11:00 a.m. ET — Presentation, 2026 Jefferies London Global Healthcare Conference. Scheduled company event
  • By year-end 2026 — Third OSPREY cohort dosing completion. Company target
  • First half of 2027 — Initial STK-002 data and planned FDA data submissions. Distinct company targets
  • Q3 2027 — EMPEROR pivotal readout. Company target
  • Second half of 2027 — Planned U.S. NDA completion. Company target, no approval implied

October 29 company update · EMPEROR trial · November investor conferences

Zorevunersen and the EMPEROR pivotal test

EMPEROR is a global randomized, double-blind, sham-controlled phase 3 study in children aged 2 to under 18 with Dravet syndrome and an eligible SCN1A variant. Patients continue background antiseizure treatment. Stoke completed enrollment of 162 patients in the United States, United Kingdom and Japan in June 2026. Those patients constitute the planned primary analysis population for the U.S. submission. Enrollment filing . The controlled treatment period lasts 52 weeks. The regimen includes two 70 mg loading doses, followed by 45 mg maintenance doses during that period. The registered primary endpoint measures seizure change at Week 28; secondary measures extend to seizure durability and adaptive behavior at Week 52. The registry describes a later treatment period in which eligible participants receive active treatment. Protocol and schedule .

Stoke cash, partner rights and development spending

Update to September 30, 2026: Stoke reported $358.8 million in cash, cash equivalents and marketable securities, which it expects to fund operations into early 2028. For the third quarter, revenue was $11.3 million, research and development expenses $59.8 million, sales, general and administrative expenses $28.7 million and net loss $73.6 million ($1.08 per share, including $11.0 million of non-cash stock-based compensation); for the nine months, net loss was $185.3 million, or $2.81 per share, against net income of $51.0 million a year earlier, when revenue included $150.8 million related to the Biogen IP license. Source The June 30 detail follows. At June 30, 2026, Stoke reported $110.004 million in cash and equivalents and $244.316 million in current and long-term marketable securities, totaling $354.320 million. A subsequent ATM sale raised $65.7 million net. The August 3 update therefore described approximately $420 million on a pro forma basis. The company expected this funding to support operations through a potential U.S. launch in early 2028. The $420 million figure is not an October cash balance. Q2 financial results .

Merlintrader Health Score · $STOK

3.80out of 5
Balance sheet and runway · 30%4.0

Substantial liquidity ($358.8 million at September 30, 2026) and management’s early-2028 horizon; high cash use leaves execution sensitivity. Source

Catalysts · 30%4.0

Defined pivotal readout and filing sequence plus OSPREY; principal efficacy risk remains concentrated in a single program. Source

Dilution · 20%3.0

Actual ATM issuance, pre-funded warrants and employee equity offset the benefit of extended funding. Source

Trading liquidity · 10%4.0

Nasdaq listing and approximately 0.93M shares average volume in the October 22 market data; liquidity can deteriorate around binary events.

Execution · 10%4.0

Primary cohort and separate European cohort enrolled, FDA discussion completed and OSPREY progressing; pivotal success and commercial execution still unproven. Source

Assessed October 22, 2026. Weighted calculation: 4.0×30% + 4.0×30% + 3.0×20% + 4.0×10% + 4.0×10% = 3.80. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.

Red flags

  • EMPEROR remains the controlled pivotal test. Early clinical observations and prespecified secondary-endpoint plans say nothing about the future result; partner rights, development costs and capital needs remain material.
  • The pivotal controlled result remains ahead. Early studies were open-label; invasive repeat administration, long-term safety, endpoint interpretation, competition, regulatory execution and further share dilution can all limit the outcome. A positive seizure result may still leave the broader disease-modification thesis unproven.

STOK Stock FAQ: Stoke Therapeutics Questions Answered

What is the next STOK stock catalyst?

Stoke’s October 29, 2026 update expects completion of dosing in OSPREY’s third STK-002 cohort by year-end 2026. Initial safety and efficacy data are anticipated in the first half of 2027. The EMPEROR data readout for zorevunersen is a later milestone, targeted for Q3 2027. Before those milestones, management is scheduled to present at the Guggenheim conference on November 10 (1:00 p.m. ET) and the Jefferies London conference on November 17 (11:00 a.m. ET), with live webcasts on the investor website. November conference schedule. OSPREY and EMPEROR milestone guidance.

Is Stoke’s zorevunersen FDA approved?

No: zorevunersen remained investigational in Stoke’s October 29, 2026 update and is being studied in Phase 3 EMPEROR for Dravet syndrome. FDA Breakthrough Therapy and orphan-drug designations support development but do not authorize commercial marketing. The company plans to complete its U.S. NDA in the second half of 2027. Investigational status and designations. Planned NDA submission.

How much cash does Stoke Therapeutics have, and how long will it last?

Stoke reported $358.8 million in cash, equivalents and marketable securities at September 30, 2026, with funding projected into early 2028. Its August 3 update had reported $420.0 million following a subsequent ATM sale, a historical amount that predates the September balance. September resources and funding outlook. August 3 funding update.

Could STOK stock be diluted by more shares?

Further STOK dilution is possible through equity awards and future share sales, as described in its filing for the quarter ended June 30, 2026. The company subsequently raised $65.7 million net through its ATM. It reported 64,813,537 common shares outstanding at September 30, 2026; weighted-average EPS denominators measure a reporting period rather than that date’s share count. Equity awards and ATM financing. September common-share balance.

When does Stoke Therapeutics report earnings?

Stoke reported Q3 2026 financial results on October 29, 2026; as of November 3, it had not announced its next financial-results date. The completed release covers the quarter ended September 30, including reported cash and collaboration revenue. Its clinical milestone windows are separate from the financial reporting schedule. Completed Q3 financial results. Company announcements. Official events calendar.

What does Stoke Therapeutics do?

As of October 29, 2026, Stoke develops RNA-based medicines intended to restore insufficient protein production. Zorevunersen, also known as STK-001, aims to increase functional NaV1.1 from the unaffected SCN1A copy and is in Phase 3 for Dravet syndrome. STK-002 is in Phase 1 development for autosomal dominant optic atrophy. Company, mechanisms and clinical programs. Zorevunersen name and platform.

When will Stoke report EMPEROR results for zorevunersen?

Stoke’s October 5, 2026 regulatory update targets EMPEROR topline in Q3 2027, followed by completion of its U.S. NDA in the second half of 2027. Early-2028 approval and launch remain potential outcomes dependent on successful development and FDA review. The trial evaluates seizures as well as cognition and behavior; the latter is a key secondary endpoint, not an established treatment benefit. EMPEROR timing, endpoints and regulatory plan.

What does Biogen’s partnership with Stoke cover?

Stoke’s filing for the quarter ended June 30, 2026 says it retains zorevunersen rights in the United States, Canada and Mexico, while Biogen holds rest-of-world rights. Specified development costs are shared 70% by Stoke and 30% by Biogen. Stoke received an upfront payment and can earn additional conditional milestones and royalties. Collaboration rights, cost sharing and economics. Current collaboration description.

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent educational research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $STOK or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.

Biotechnology companies face clinical, safety, regulatory, manufacturing, commercial and financing risks. Trials can fail, adverse effects can limit use, regulatory applications can be delayed or rejected, and an approved medicine may not achieve commercial expectations. Additional borrowing or equity issuance can increase obligations or dilute existing shareholders. Investors can lose part or all of their capital. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.